

# 2019 Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections R&D Pipeline Drugs, Companies, Trials and Developments

<https://marketpublishers.com/r/2C4799DC798EN.html>

Date: March 2019

Pages: 40

Price: US\$ 2,199.00 (Single User License)

ID: 2C4799DC798EN

## Abstracts

The global demand for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections treatment options is expected to report strong growth over the medium to long term future driven by consumption in major markets. Strong growth prospects of drugs for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections are driving leading companies to invest their resources on the pipeline.

Companies quickly advancing their drug candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and inadequate financial support are holding some of the Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections pipeline companies from advancing their products.

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Report Description

The H1-2019 pipeline review report on Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections is a comprehensive study on drug candidates across different phases worldwide. This report evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date.

The Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections pipeline guide presents information on all active drugs currently being developed for Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections pipeline candidate are analyzed.

Further, current phase of development, mechanism of action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

The publisher has developed the report based on robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections pipeline report includes-

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise pipeline compounds

Company wise list of pipeline compounds

Mechanism of Action wise pipeline compounds

For each pipeline product, the following details are provided-

Snapshot (Drug, , Phase, Co Developer, Originator, Synonym, Orphan Drug Status, Type of Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials

## **REASONS TO BUY**

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into the market through in-depth strategic analysis review

Know the list of companies participating in global Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

## Contents

### **GLOBAL HOSPITAL ACQUIRED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (HA-MRSA) INFECTIONS PIPELINE OVERVIEW**

Key Findings, 2019  
Disease Overview  
Report Guide and Research Methodology

#### **EXECUTIVE SUMMARY**

Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections  
Drugs under active development, H1 @2019  
Pipeline Drugs in Early Stage of Development (Pre-clinical, Discovery, Phase 1 and Phase 2)  
Pipeline Drugs in Advanced Stage of Development (Phase 3, Pre-registration)  
Companies involved in Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections pipeline, H1 @2019  
Mechanism of Action wise Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA) Infections Pipeline Candidates

### **DESTINY PHARMA LTD HOSPITAL ACQUIRED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (HA-MRSA) INFECTIONS PIPELINE DETAILS**

Business Profile  
Drug Details  
  Drug Snapshot  
  Originator  
  Collaborator/Co-Developer  
  Route of Administration  
  Orphan Drug/Fast Track/Special Designation  
  Area  
  Type of Molecular Entity  
Current Status  
Drug Overview  
Drug Mechanism of Action  
Clinical/Pre-clinical Trial Details  
Latest Drug Developments

**MGB BIOPHARMA LTD HOSPITAL ACQUIRED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (HA-MRSA) INFECTIONS PIPELINE DETAILS**

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

**SYNTIRON LLC HOSPITAL ACQUIRED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (HA-MRSA) INFECTIONS PIPELINE DETAILS**

Business Profile

Drug Details

Drug Snapshot

Originator

Collaborator/Co-Developer

Route of Administration

Orphan Drug/Fast Track/Special Designation

Area

Type of Molecular Entity

Current Status

Drug Overview

Drug Mechanism of Action

Clinical/Pre-clinical Trial Details

Latest Drug Developments

**TECHULON INC HOSPITAL ACQUIRED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (HA-MRSA) INFECTIONS PIPELINE DETAILS**

Business Profile  
Drug Details  
  Drug Snapshot  
  Originator  
  Collaborator/Co-Developer  
  Route of Administration  
  Orphan Drug/Fast Track/Special Designation  
  Area  
  Type of Molecular Entity  
Current Status  
Drug Overview  
Drug Mechanism of Action  
Clinical/Pre-clinical Trial Details  
Latest Drug Developments

## **VALEVIA UK LTD HOSPITAL ACQUIRED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (HA-MRSA) INFECTIONS PIPELINE DETAILS**

Business Profile  
Drug Details  
  Drug Snapshot  
  Originator  
  Collaborator/Co-Developer  
  Route of Administration  
  Orphan Drug/Fast Track/Special Designation  
  Area  
  Type of Molecular Entity  
Current Status  
Drug Overview  
Drug Mechanism of Action  
Clinical/Pre-clinical Trial Details  
Latest Drug Developments

## **LATEST HOSPITAL ACQUIRED METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (HA-MRSA) INFECTIONS DRUG PIPELINE DEVELOPMENTS, 2019**

### **APPENDIX**

About Us

Sources and Methodology  
Contact Information



## I would like to order

Product name: 2019 Hospital Acquired Methicillin-Resistant Staphylococcus aureus (HA-MRSA)  
Infections R&D Pipeline Drugs, Companies, Trials and Developments

Product link: <https://marketpublishers.com/r/2C4799DC798EN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2C4799DC798EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

